Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems

Singh, Jasvinder; Pandit, S.; Bramwell, Vincent W.; Alpar, H. Oya

doi:10.1016/j.ymeth.2005.11.003

Cited by 108 publications

(56 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PCL suffers in vivo hydrolysis releasing monomers that are absorbed, metabolized and eliminated by organism. 13 PCL nanoparticles have been used as drugs delivery systems for amphotericin B, 14 indometacin, 15 griseofulvin, 16 tamoxifen, 17 vaccines, 18 and cyclosporine A. 19 In this work, PCL nanoparticles were produced by solvent emulsion evaporation method suitable for encapsulation of hydrophobic drugs like as NPX.…”

Section: Introductionmentioning

confidence: 99%

Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies

Mello¹,

Ricci-Júnior²

2011

Quím. Nova

View full text Add to dashboard Cite

Recebido em 7/6/10; aceito em 10/1/11; publicado na web em 25/3/11 Nanoparticles were produced by solvent emulsification evaporation method with the following characteristics: nanometric size (238 ± 3 nm), narrow polydispersity index (0.11), negative zeta potential (-15.1 mV), good yield of the process (73 ± 1.5%), excellent encapsulation efficiency (81.3 ± 4.2%) and spherical shape. X-rays diffraction demonstrated the loss of drug crystallinity after encapsulation; however, the profile of the diffractograms of the poly-ε-caprolactone (PCL) nanoparticles was kept. Differential scanning calorimetry thermograms, correspondingly, exhibited the loss of drug melting peak and the increasing of the melting point of the PCL nanoparticles, evidencing an interaction drug-polymer. Naproxen release was low and sustained obeying the Higuchi´s kinetic. The results show that nanoparticles are promising sustained release system to the naproxen.

show abstract

Section: Introductionmentioning

confidence: 99%

Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies

Mello¹,

Ricci-Júnior²

2011

Quím. Nova

View full text Add to dashboard Cite

show abstract

“…Other researchers have reported that unmethylated CpG motifs may facilitate the oral delivery of protein antigens. Finally, amicroneedlemediated vaccine delivery system is thought to warrant further investigation as a convenient method of transcutaneous immunization, although it does not induce an IgA immune response [2,8,33,34,59,65,72,107,108,110,[117][118][119][120][121]. An oral diphtheria vaccine based on formaldehyde-and lysine-inactivated CRM197 conjugated with a starch microparticle was trialed in humans some years ago, following successful tests in mice.…”

Section: Oral and Transcutaneous Vaccine Delivery Systemsmentioning

confidence: 99%

“…Another approach to oral delivery systems for convenient immunization against diphtheria uses nanoparticles of modified PLA and PLGA, or poly-epsilon-caprolactone (PCL) and PLGA copolymer, in which diphtheria toxoid is encapsulated by spray drying. In vitro results indicate that PCL nanoparticles have the best capability for transporting diphtheria toxoid into Caco-2 cells, a human colon carcinoma cell line [59,119].…”

Section: Oral and Transcutaneous Vaccine Delivery Systemsmentioning

confidence: 99%

The Evolution and Value of Diphtheria Vaccine

Bae¹

2011

KSBB Journal

View full text Add to dashboard Cite

1) This review article provides an overview of the evolution of diphtheria vaccine, its value and its future. Diphtheria is an infectious illness caused by diphtheria toxin produced by pathogenic strains of Corynebacterium diphtheriae. It is characterized by a sore throat with membrane formation due to local tissue necrosis, which can lead to fatal airway obstruction; neural and cardiac damage are other common complications. Diphtheria vaccine was first brought to market in the 1920s, following the discovery that diphtheria toxin can be detoxified using formalin. However, conventional formalin-inactivated toxoid vaccines have some fundamental limitations. Innovative technologies and approaches with the potential to overcome these limitations are discussed in this paper. These include genetic inactivation of diphtheria toxoid, innovative vaccine delivery systems, new adjuvants (both TLRindependent and TLR-dependent adjuvants), and heat-and freeze-stable agents, as well as novel platforms for producing improved conventional vaccine, DNA vaccine, transcutaneous (microneedle-mediated) vaccine, oral vaccine and edible vaccine expressed in transgenic plants. These innovations target improvements in vaccine quality (efficacy, safety, stability and consistency), ease of use and/or thermal stability. Their successful development and use should help to increase global diphtheria vaccine coverage.

show abstract

“…Drugs are incorporated into nanoparticles by dissolution, entrapment, adsorption, attachment or by encapsulation, and the nanoparticles provide sustained release of the drugs for longer periods, e.g., days and weeks 3 . Nanoparticles enhance immunization by prevention of degradation of the vaccine and increased uptake by immune cells 4 . One of the determinants of the extent of uptake by immune cells is the type of polymer employed.…”

Section: Materials and Types Of Nanostructures Polymeric Nanoparticlesmentioning

confidence: 99%

“…One of the determinants of the extent of uptake by immune cells is the type of polymer employed. In a study 4 comparing poly-(ε-caprolactone) (PCL), poly (lactide-coglycolide) (PLGA) and their blend, PCL nanoparticles were the most efficiently taken up by immune cells due to their hydrophobicity. However, all polymeric nanoparticles elicited vaccine (diphtheria toxoid) specific serum IgG antibody response significantly higher than free diphtheria toxoid.…”

Section: Materials and Types Of Nanostructures Polymeric Nanoparticlesmentioning

confidence: 99%

Nanotechnology and Drug Delivery Part 2: Nanostructures for Drug Delivery

Ochekpe¹,

Olorunfemi²,

Ngwuluka³

2009

Trop. J. Pharm Res

View full text Add to dashboard Cite

show abstract

Diphtheria toxoid loaded poly-(ε-caprolactone) nanoparticles as mucosal vaccine delivery systems

Cited by 108 publications

References 43 publications

Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies

Encapsulation of naproxen in nanostructured system: structural characterization and in vitro release studies

The Evolution and Value of Diphtheria Vaccine

Nanotechnology and Drug Delivery Part 2: Nanostructures for Drug Delivery

Contact Info

Product

Resources

About